瑞银发表研报指，信达生物(01801.HK) 2024年下半年业绩胜预期，Non-IFRS首度实现收支平衡。
基于2024年业绩，以及即将来临的新一轮集中采购，瑞银下调信达生物生物类似药的收入预测，同时上调公司今年开支预测，以反映对于新产品上市的营销费用增加，相应略为下调今年每股盈利预测，目标价从61.4元降至59元，评级“买入”。(gc/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-26 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.